Abstract
Background
Exogenous surfactant is currently administered via intra-tracheal instillation, a method which can increase the possibility of clinical instability in the peri-surfactant administration period. Since its introduction, there has been an increase in understanding of the pathology of respiratory distress syndrome and surfactant biology. This includes development of a potential nebulized surfactant which has the potential to increase the number, safety and timely administration of the medication in preterm infants.
Data sources
Based on recent original publications in the field of surfactant biology, we reviewed our experience with surfactant administration and discussed the available evidence on nebulized surfactant and outlined potential barriers toward widespread introduction of this therapy.
Results
Surfactant has revolutionized modern neonatal management and nebulized surfactant is attractive and a vector for administration. However, issues regarding costeffectiveness, development of nebulizer devices capable of administration, deposition of medication in the airway and dosing strategies remain unresolved.
Conclusions
Nebulized surfactant has the potential to be a therapeutic breakthrough by eliminating the potent volu-and-baro-traumatic effects of mechanical ventilation in the peri-surfactant period. Nebulization would likely lead to increased administration immediately after birth and more emphasis on noninvasive ventilator strategies. These features will aid clinical implementation of nebulized surfactant as a standard of treatment after introduction.
Similar content being viewed by others
References
Halliday HL. Recent clinical trials of surfactant treatment for neonates. Biol Neonate 2006;89:323–329.
Stevens TP, Sinkin RA. Surfactant replacement therapy. Chest 2007;131:1577–1582.
Morley CJ, Bangham AD, Miller N, Davis JA. Dry artificial lung surfactant and its effect on very premature babies. Lancet 1981;1:64–68.
Bangham AD. Lung surfactant: how it does and does not work. Lung 1987;165:17–25.
Hawgood S. Surfactant protein B: structure and function. Biol Neonate 2004;85:285–289.
Broussard D, Larson JE, Cohen JC, Lundblad LK. Developmental changes in respiratory mechanics in the neonatal rat. Exp Lung Res 2006;32:263–273.
Ramanathan R. Surfactants in the management of respiratory distress syndrome in extremely premature infants. J Pediatr Pharmacol Ther 2006;11:132–144.
Finer NN. Surfactant use for neonatal lung injury: beyond respiratory distress syndrome. Paediatr Respir Rev 2004;5Suppl A:S289–297.
Greenough A. Expanded use of surfactant replacement therapy. Eur J Pediatr 2000;159:635–640.
Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005;293:470–476.
Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;155:1309–1315.
Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991;87:101–107.
Chinese Collaborative Study Group for Neonatal Respiratory Diseases. Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trial. Acta Paediatr 2005;94:896–902.
Soll RF, Dargaville P. Surfactant for meconium aspiration syndrome in full term infants. Cochrane Database Syst Rev 2000;(2):CD002054.
Yost CC, Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2000;(2):CD001456.
Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001;(2):CD000144.
Sinha S, Moya F, Donn SM. Surfactant for respiratory distress syndrome: are there important clinical differences among preparations? Curr Opin Pediatr 2007;19:150–154.
Ainsworth SB, Beresford MW, Milligan DW, Shaw NJ, Matthews JN, Fenton AC, et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25–29 weeks’ gestation: a randomised trial. Lancet 2000; 355:1387–1392.
Merritt TA, Kheiter A, Cochrane CG. Positive end-expiratory pressure during KL4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome. Pediatr Res 1995;38:211–217.
Thomson MA. Continuous positive airway pressure and surfactant; combined data from animal experiments and clinical trials. Biol Neonate 2002;81Suppl 1:16–19.
Hilgendorff A, Reiss I, Ruppert C, Hanfstingl T, Seliger AS, Gunther A, et al. Positive end-expiratory pressure modifies response to recombinant and natural exogenous surfactant in ventilated immature newborn rabbits. Biol Neonate 2006;90: 210–216.
Horbar JD, Carpenter JH, Buzas J, Soll RF, Suresh G, Bracken MB, et al. Timing of initial surfactant treatment for infants 23 to 29 weeks’ gestation: is routine practice evidence based? Pediatrics 2004;113:1593–602.
Finer NN, Rich W, Craft A, Henderson C. Comparison of methods of bag and mask ventilation for neonatal resuscitation. Resuscitation 2001;49:299–305.
American Academy of Pediatrics/American Heart Association. Use of Resuscitation Devices for Positive Pressure Ventilation in Textbook of Neonatal Resuscitation. In: Kattwinkel J, eds. Textbook of Neonatal Resuscitation, 5th ed. Elk Grove Village, 2006: 3-1–3-58.
Marshall TA, Deeder R, Pai S, Berkowitz GP, Austin TL. Physiologic changes associated with endotracheal intubation in preterm infants. Crit Care Med 1984;12:501–503.
Lane B, Finer N, Rich W. Duration of intubation attempts during neonatal resuscitation. J Pediatr 2004;145:67–70.
Bradley JS, Billows GL, Olinger ML, Boha SP, Cordell WH, Nelson DR. Prehospital oral endotracheal intubation by rural basic emergency medical technicians. Ann Emerg Med 1998; 32:26–32.
Falck AJ, Escobedo MB, Baillargeon JG, Villard LG, Gunkel JH. Proficiency of pediatric residents in performing neonatal endotracheal intubation. Pediatrics 2003;112:1242–1247.
Leone TA, Rich W, Finer NN. Neonatal intubation: success of pediatric trainees. J Pediatr 2005;146:638–641.
Geller D. The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 2008;43:S5–S17.
Zanen P, Laube BL. Targeting the Lungs with Theraputic Aerosols. In: Bisgaard H, O’Callaghan CO, Smaldone GC, eds. Drug Delivery to the Lung. New York: NY Marcel Dekker Inc, 2002: 211–225.
Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588–599.
Laube BL, Jashnani R, Dalby RN, Zeitlin PL. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 2000;118:1069–1076.
Stocks J, Hislop A. Structure and function of the respiratory system. Developmental aspects and their relevance to aerosol therapy. In: Bisgaard H, O’Callaghan C, Smaldone G, eds. Drug delivery to the lung. New York: Marcel Dekker, 2002: 47–104.
Mazela J, Merritt TA, Finer NN. Aerosolized surfactants. Curr Opin Pediatr 2007;19:155–162.
Jorch G, Hartl H, Roth B, Kribs A, Gortner L, Schaible T, et al. Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonol 1997;24:222–224.
Berggren E, Liljedahl M, Winbladh B, Andreasson B, Curstedt T, Robertson B, et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr 2000;89:460–464.
Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Liu G. A multicenter pilot study of Aerosurf™ delivered via nasal continuous positive airway pressure (nCPAP) to prevent respiratory distress syndrome in preterm neonates. Pediatr Res 2006;59:PAS2006:4840.138
Arroe M, Pedersen-Bjergaard L, Albertsen P, Bode S, Greisen G. Inhalation of aerosolized surfactant (Exosurf) to neonates treated with continuous positive airway pressure. Prenat Neonat Med 1998;3:346–352.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shah, S. Exogenous surfactant: intubated present, nebulized future?. World J Pediatr 7, 11–15 (2011). https://doi.org/10.1007/s12519-010-0201-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-010-0201-4